Defence Therapeutics Key Platform Patent Accepted Broadly Covering Vaccine Technology
Vancouver, British Columbia--(Newsfile Corp. - November 7, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing cutting-edge vaccines, therapeutics, and drug delivery technologies against cancer and other diseases, is pleased to announce that the Canadian Intellectual Property Office (CIPO) has issued a Notice of allowance for Defence's Canadian patent application no. 3,201,103.Canadian patent...
2023-11-07 3:15 AM EST
Defence's AccuTOX(R) And Antigen Cross-Presentation: Discovery Leads Towards the Development of a Groundbreaking Platform
Vancouver, British Columbia--(Newsfile Corp. - October 25, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a leading Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce the discovery of a novel function for its lead anticancer injectable drug AccuTOX® in the context of cell-based cancer vaccine engineering. The objective of the Accum®...
2023-10-25 3:15 AM EDT
Defence's Novel Accutox(TM) Continues to Surprise on Results Against Cancer
Vancouver, British Columbia--(Newsfile Corp. - October 18, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that the excitement around AccuTOXTM against cancer continues to develop and expand its applications. The AccuTOXTM molecule can eradicate cancer cells via different mechanisms...
2023-10-18 3:15 AM EDT
Defence's Delivery of Encapsulated AccuTOX(TM)-Chitosan Nanoparticles Triggers Complete Tumor Regression in Animals with Pre-Established Solid Lymphoma
Vancouver, British Columbia--(Newsfile Corp. - October 17, 2023) - Defence Therapeutics Inc. (CSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that systemic administration of novel AccuTOXTM-chitosan encapsulated formulation inhibits the growth of pre-established solid lymphoma resulting in their progressive shrinking over time.The conducted study had...
2023-10-17 3:15 AM EDT
Defence Announces Peer-reviewed Publication of Its Preclinical Data on Accum(R) as an Anti-Cancer Molecule in the Journal of Cancer Science
Vancouver, British Columbia--(Newsfile Corp. - October 10, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a biotechnology company developing various products for the immune-oncology vaccines and drug delivery technologies, is pleased to announce the publication of a peer-reviewed study on the anticancer properties of its unconjugated Accum®, one of Defence's product designed notably to treat established T-cell lymphoma. The study, which...
2023-10-10 3:15 AM EDT
Defence to Present Three of Its Leading Products at the Upcoming Festival of Biologics in Basel, Switzerland
Vancouver, British Columbia--(Newsfile Corp. - October 6, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce its participation to the upcoming Festival of Biologics to be held in Basel, Switzerland, October 10-12, 2023. The Festival of Biologics is a hub for the life science community to...
2023-10-06 6:00 PM EDT
Defence's Accum(R)-mRNA Lipid Nanoparticles Elicit Antibody Response 2X Stronger than Standard mRNA Vaccines
Vancouver, British Columbia--(Newsfile Corp. - September 25, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that its encapsulation strategy used to generate Accum®-mRNA lipid nanoparticles (LNPs) results in an antibody response that is twice as potent as standard mRNA LNPs. These results...
2023-09-25 3:15 AM EDT
Defence to Collaborate with Native Ads for Marketing Campaign
Vancouver, British Columbia--(Newsfile Corp. - September 22, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce it has entered into a service agreement with Native Ads Inc. ("Native Ads"), pursuant to which Native Ads will provide a marketing campaign for a total retainer of up to US$250,000,...
2023-09-22 4:00 PM EDT
Defence's Broad and Versatile Accum(R) Technology Platform Focus on Cancer Therapeutics
Vancouver, British Columbia--(Newsfile Corp. - September 12, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), one of the leading Canadian biotechnology companies, is pleased to announce its continuation to bringing innovative strategies aimed at targeting various indications related to immune-oncology.Whether using an antibody, cell-based vaccine or small molecule therapeutics, the common denominator in all of Defence's development...
2023-09-12 3:15 AM EDT
Defence's Innovative Therapeutics Featured on Viewpoint with Dennis Quaid
Vancouver, British Columbia--(Newsfile Corp. - September 5, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company") a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies is pleased to announce that Viewpoint, the educational television show distributed nationally and hosted by veteran actor Dennis Quaid, is gearing up with content providers to share information regarding breakthroughs in...
2023-09-05 3:15 AM EDT
Defence Successfully Completes the First Milestone of Its Collaboration Agreement with Orano
Vancouver, British Columbia--(Newsfile Corp. - July 18, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company") is pleased to announce that it has successfully reached the first milestone established in the Collaboration Agreement with Orano Support SAS on behalf of Orano SA ("Orano"), a world-renowned multinational company, headquartered in Chatillon, France, to develop the next generation radio-immunoconjugates using Defence's intracellular...
2023-07-18 3:15 AM EDT
RETRANSMISSION: Defence and Viewpoint with Dennis Quaid Join Forces to Explore Breakthroughs in Biotechnology
Vancouver, British Columbia--(Newsfile Corp. - July 5, 2023) - Defence Therapeutics Inc. ("Defence" or the "Company") a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies is pleased to announce its collaboration with Viewpoint with Dennis Quaid. This exciting partnership aims to explore breakthroughs in biotechnology and highlight the transformative potential of cutting-edge therapeutics.Defence Therapeutics Inc., with its commitment to...
2023-07-05 3:15 AM EDT
Defence and Viewpoint with Dennis Quaid Join Forces to Explore Breakthroughs in Biotechnology
Vancouver, British Columbia--(Newsfile Corp. - July 4, 2023) - Defence Therapeutics Inc. ("Defence" or the "Company") a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies is pleased to announce its collaboration with Viewpoint with Dennis Quaid. This exciting partnership aims to explore breakthroughs in biotechnology and highlight the transformative potential of cutting-edge therapeutics.Defence Therapeutics Inc., with its commitment to...
2023-07-04 3:15 AM EDT
Defence Patent Portfolio at the Forefront of Success
Vancouver, British Columbia--(Newsfile Corp. - June 28, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company") is a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies. Sitting at the core of its innovative technologies is the proprietary Accum™-based platform, which Defence is harnessing to develop innovative therapeutics and prophylactics against cancers and infectious diseases.Although...
2023-06-28 10:30 AM EDT
Defence's Proprietary Accum(TM) Technology for Delivery of CRISPR/Cas Genome-Editing Complexes Patent Application Published
Vancouver, British Columbia--(Newsfile Corp. - June 20, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce the publication of its new international (PCT) patent application demonstrating the effectiveness of Defence's AccumTM-based technology to intracellularly deliver a wide variety of cargoes while...
2023-06-20 3:15 AM EDT
Defence Manufacturing of AccuTox(TM) CGMP Final Drug Product Optimization for Its Phase I Clinical Trial at City of Hope
Vancouver, British Columbia--(Newsfile Corp. - June 16, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce that it reached the final stages of its AccuTOXTM Chemistry, Manufacturing and Controls ("CMC") in preparation to IND filling for its Phase I clinical trial to treat melanoma patients at...
2023-06-16 3:15 AM EDT
Defence Begins Testing Its Arm Vaccine Against Pancreatic Cancer
Vancouver, British Columbia--(Newsfile Corp. - June 6, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce that it mandated Transbiotech Biotechnology Research and Transfer Center to initiate testing its cellular anti-cancer ARM vaccine against deadly pancreatic cancer. Using the AccumTM...
2023-06-06 3:15 AM EDT
Defence Announces Additional and Final Exercises of Warrants for Gross Proceeds of Over $2.3 Million
Vancouver, British Columbia--(Newsfile Corp. - May 26, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that, in addition to the previously announced proceeds of $5,494,375 on March 17, 2023, it has received additional proceeds in the aggregate amount of $2,308,625 from the exercise of...
2023-05-26 5:00 PM EDT
Breakthrough Results: Defence's Arm Vaccine Cured 100% of Animals with Pre-Established Lymphoma
Vancouver, British Columbia--(Newsfile Corp. - May 24, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce the successful completion of a pre-clinical study evaluating the therapeutic potency of a second-generation ARM vaccine targeting solid tumors.The AccumTM technology holds a promising...
2023-05-24 3:15 AM EDT
Defence's Successful AccuTOX(TM) Pre-Clinical Efficacy Study Complete Ready For Phase I IND Filing
Vancouver, British Columbia--(Newsfile Corp. - May 2, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce the successful completion of all required pre-clinical efficacy studies regarding its AccuTOXTM program. AccuTOXTM is one of Defence's most advanced research and development program....
2023-05-02 3:15 AM EDT